ID   ARI1B_HUMAN             Reviewed;        2236 AA.
AC   Q8NFD5; Q5JRD1; Q5VYC4; Q8IZY8; Q8TEV0; Q8TF02; Q99491; Q9ULI5;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   30-AUG-2005, sequence version 2.
DT   22-JUL-2015, entry version 130.
DE   RecName: Full=AT-rich interactive domain-containing protein 1B;
DE            Short=ARID domain-containing protein 1B;
DE   AltName: Full=BRG1-associated factor 250b;
DE            Short=BAF250B;
DE   AltName: Full=BRG1-binding protein hELD/OSA1;
DE   AltName: Full=Osa homolog 2;
DE            Short=hOsa2;
DE   AltName: Full=p250R;
GN   Name=ARID1B; Synonyms=BAF250B, DAN15, KIAA1235, OSA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), AND IDENTIFICATION IN THE
RP   EPAFB COMPLEX.
RC   TISSUE=Brain;
RX   PubMed=11734557; DOI=10.1074/jbc.M108702200;
RA   Kato H., Tjernberg A., Zhang W., Krutchinsky A.N., An W., Takeuchi T.,
RA   Ohtsuki Y., Sugano S., de Bruijn D.R., Chait B.T., Roeder R.G.;
RT   "SYT associates with human SNF/SWI complexes and the C-terminal region
RT   of its fusion partner SSX1 targets histones.";
RL   J. Biol. Chem. 277:5498-5505(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-515.
RX   PubMed=9804814; DOI=10.1074/jbc.273.46.30466;
RA   Mangel L., Ternes T., Schmitz B., Doerfler W.;
RT   "New 5'-(CGG)-3' repeats in the human genome.";
RL   J. Biol. Chem. 273:30466-30471(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-199.
RX   PubMed=8896557; DOI=10.1038/ng1196-285;
RA   Imbert G., Saudou F., Yvert G., Devys D., Trottier Y., Garnier J.-M.,
RA   Weber C., Mandel J.-L., Cancel G., Abbas N., Duerr A., Didierjean O.,
RA   Stevanin G., Agid Y., Brice A.;
RT   "Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with
RT   high sensitivity to expanded CAG/glutamine repeats.";
RL   Nat. Genet. 14:285-291(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 72-2236 (ISOFORM 1), TISSUE SPECIFICITY,
RP   INTERACTION WITH SMARCA2 AND SMARCA4, AND IDENTIFICATION IN A
RP   SWI/SNF-LIKE COMPLEX WITH ARID1A.
RX   PubMed=12200431; DOI=10.1074/jbc.M205961200;
RA   Inoue H., Furukawa T., Giannakopoulos S., Zhou S., King D.S.,
RA   Tanese N.;
RT   "Largest subunits of the human SWI/SNF chromatin-remodeling complex
RT   promote transcriptional activation by steroid hormone receptors.";
RL   J. Biol. Chem. 277:41674-41685(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 272-2236 (ISOFORM 1), TISSUE
RP   SPECIFICITY, IDENTIFICATION BY MASS SPECTROMETRY, AND IDENTIFICATION
RP   IN A SWI/SNF-LIKE EPAFB COMPLEX.
RX   PubMed=12665591; DOI=10.1128/MCB.23.8.2942-2952.2003;
RA   Nie Z., Yan Z., Chen E.H., Sechi S., Ling C., Zhou S., Xue Y.,
RA   Yang D., Murray D., Kanakubo E., Cleary M.L., Wang W.;
RT   "Novel SWI/SNF chromatin-remodeling complexes contain a mixed-lineage
RT   leukemia chromosomal translocation partner.";
RL   Mol. Cell. Biol. 23:2942-2952(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 491-2236 (ISOFORM 2), SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, INTERACTION WITH SMARCA4, IDENTIFICATION
RP   IN A COMPLEX WITH SMARCA4 AND SMARCD1, AND IDENTIFICATION IN A
RP   SWI/SNF-LIKE COMPLEX WITH ARID1A.
RX   PubMed=11988099;
RA   Hurlstone A.F., Olave I.A., Barker N., van Noort M., Clevers H.;
RT   "Cloning and characterization of hELD/OSA1, a novel BRG1 interacting
RT   protein.";
RL   Biochem. J. 364:255-264(2002).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 705-2236 (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=10574462; DOI=10.1093/dnares/6.5.337;
RA   Nagase T., Ishikawa K., Kikuno R., Hirosawa M., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XV.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:337-345(1999).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-516; SER-1555 AND
RP   SER-1559, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS], AND CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1777, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1555 AND SER-1559, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1555 AND SER-1715, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   INVOLVEMENT IN MRD12, AND VARIANTS ALA-11 INS; 45-ALA--ALA-47 DEL;
RP   HIS-82; SER-246; 318-GLY-GLY-319 DEL; GLY-319 DEL; 327-GLY-GLY-328
RP   DEL; 333-GLY--GLY-337 DEL; VAL-363; ALA-396; VAL-429; PRO-450 INS;
RP   ASN-497; THR-531; GLU-876; LEU-980; ILE-1092; PRO-1249; GLU-1271;
RP   ARG-1303; ASN-1321; SER-1411; LYS-1466; HIS-1506; MET-1573; SER-1659;
RP   GLU-1733 DEL; ARG-1773; ASN-1851; ARG-1898; ARG-1954 AND ARG-2163.
RX   PubMed=22405089; DOI=10.1016/j.ajhg.2012.02.007;
RA   Hoyer J., Ekici A.B., Endele S., Popp B., Zweier C., Wiesener A.,
RA   Wohlleber E., Dufke A., Rossier E., Petsch C., Zweier M., Gohring I.,
RA   Zink A.M., Rappold G., Schrock E., Wieczorek D., Riess O., Engels H.,
RA   Rauch A., Reis A.;
RT   "Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-
RT   remodeling complex, is a frequent cause of intellectual disability.";
RL   Am. J. Hum. Genet. 90:565-572(2012).
RN   [16]
RP   INVOLVEMENT IN MRD12.
RX   PubMed=22426308; DOI=10.1038/ng.2219;
RA   Tsurusaki Y., Okamoto N., Ohashi H., Kosho T., Imai Y., Hibi-Ko Y.,
RA   Kaname T., Naritomi K., Kawame H., Wakui K., Fukushima Y., Homma T.,
RA   Kato M., Hiraki Y., Yamagata T., Yano S., Mizuno S., Sakazume S.,
RA   Ishii T., Nagai T., Shiina M., Ogata K., Ohta T., Niikawa N.,
RA   Miyatake S., Okada I., Mizuguchi T., Doi H., Saitsu H., Miyake N.,
RA   Matsumoto N.;
RT   "Mutations affecting components of the SWI/SNF complex cause Coffin-
RT   Siris syndrome.";
RL   Nat. Genet. 44:376-378(2012).
RN   [17]
RP   INVOLVEMENT IN MRD12.
RX   PubMed=22426309; DOI=10.1038/ng.2217;
RA   Santen G.W., Aten E., Sun Y., Almomani R., Gilissen C., Nielsen M.,
RA   Kant S.G., Snoeck I.N., Peeters E.A., Hilhorst-Hofstee Y.,
RA   Wessels M.W., den Hollander N.S., Ruivenkamp C.A., van Ommen G.J.,
RA   Breuning M.H., den Dunnen J.T., van Haeringen A., Kriek M.;
RT   "Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause
RT   Coffin-Siris syndrome.";
RL   Nat. Genet. 44:379-380(2012).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   REVIEW ON SWI/SNF CHROMATIN REMODELING COMPLEXES.
RX   PubMed=12672490; DOI=10.1016/S0959-437X(03)00022-4;
RA   Martens J.A., Winston F.;
RT   "Recent advances in understanding chromatin remodeling by SWI/SNF
RT   complexes.";
RL   Curr. Opin. Genet. Dev. 13:136-142(2003).
RN   [20]
RP   DNA-BINDING, IDENTIFICATION IN SWI/SNF COMPLEXES, AND INTERACTION WITH
RP   SMARCA2; SMARCA4 AND SMARCC1.
RX   PubMed=15170388; DOI=10.1042/BJ20040524;
RA   Wang X., Nagl N.G., Wilsker D., Van Scoy M., Pacchione S., Yaciuk P.,
RA   Dallas P.B., Moran E.;
RT   "Two related ARID family proteins are alternative subunits of human
RT   SWI/SNF complexes.";
RL   Biochem. J. 383:319-325(2004).
RN   [21]
RP   DNA-BINDING.
RX   PubMed=14982958; DOI=10.1093/nar/gkh277;
RA   Wilsker D., Patsialou A., Zumbrun S.D., Kim S., Chen Y., Dallas P.B.,
RA   Moran E.;
RT   "The DNA-binding properties of the ARID-containing subunits of yeast
RT   and mammalian SWI/SNF complexes.";
RL   Nucleic Acids Res. 32:1345-1353(2004).
RN   [22]
RP   IDENTIFICATION IN THE BAF COMPLEX, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=18765789; DOI=10.1101/gad.471408;
RA   Lange M., Kaynak B., Forster U.B., Toenjes M., Fischer J.J., Grimm C.,
RA   Schlesinger J., Just S., Dunkel I., Krueger T., Mebus S., Lehrach H.,
RA   Lurz R., Gobom J., Rottbauer W., Abdelilah-Seyfried S., Sperling S.;
RT   "Regulation of muscle development by DPF3, a novel histone acetylation
RT   and methylation reader of the BAF chromatin remodeling complex.";
RL   Genes Dev. 22:2370-2384(2008).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 1041-1159.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of the HBAF250B AT-rich interaction domain
RT   (ARID).";
RL   Submitted (OCT-2006) to the PDB data bank.
RN   [24]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-814.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Involved in transcriptional activation and repression of
CC       select genes by chromatin remodeling (alteration of DNA-nucleosome
CC       topology). Belongs to the neural progenitors-specific chromatin
CC       remodeling complex (npBAF complex) and the neuron-specific
CC       chromatin remodeling complex (nBAF complex). During neural
CC       development a switch from a stem/progenitor to a post-mitotic
CC       chromatin remodeling mechanism occurs as neurons exit the cell
CC       cycle and become committed to their adult state. The transition
CC       from proliferating neural stem/progenitor cells to post-mitotic
CC       neurons requires a switch in subunit composition of the npBAF and
CC       nBAF complexes. As neural progenitors exit mitosis and
CC       differentiate into neurons, npBAF complexes which contain
CC       ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous
CC       alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits
CC       in neuron-specific complexes (nBAF). The npBAF complex is
CC       essential for the self-renewal/proliferative capacity of the
CC       multipotent neural stem cells. The nBAF complex along with CREST
CC       plays a role regulating the activity of genes essential for
CC       dendrite growth (By similarity). Binds DNA non-specifically.
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Component of SWI/SNF chromatin remodeling complexes, in
CC       some of which it can be mutually exclusive with ARID1A/BAF250A.
CC       Component of the BAF (SWI/SNF-A) complex, which includes at least
CC       actin (ACTB), ARID1A, ARID1B/BAF250, SMARCA2,
CC       SMARCA4/BRG1/BAF190A, ACTL6A/BAF53, ACTL6B/BAF53B, SMARCE1/BAF57,
CC       SMARCC1/BAF155, SMARCC2/BAF170, SMARCB1/SNF5/INI1, and one or more
CC       of SMARCD1/BAF60A, SMARCD2/BAF60B, or SMARCD3/BAF60C. In muscle
CC       cells, the BAF complex also contains DPF3. Component of the
CC       SWI/SNF-B (PBAF) complex, at least composed of
CC       SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, ACTL6A/BAF53A or
CC       ACTL6B/BAF53B, SMARCE1/BAF57, SMARCD1/BAF60A, SMARCD2/BAF60B,
CC       perhaps SMARCD3/BAF60C, SMARCC1/BAF155, SMARCC2/BAF170,
CC       PB1/BAF180, ARID2/BAF200, ARID1A/BAF250A or ARID1B/BAF250B and
CC       actin. Component of a SWI/SNF-like EPAFb complex, at least
CC       composed of SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, ACTL6A/BAF53A,
CC       SMARCE1/BAF57, SMARCD1/BAF60A, SMARCD2/BAF60B, SMARCC1/BAF155,
CC       SMARCC2/BAF170, ARID1B/BAF250B, MLLT1/ENL and actin. Component of
CC       a SWI/SNF-like complex containing ARID1A/BAF250A and
CC       ARID1B/BAF250B. Interacts through its C-terminus with
CC       SMARCA2/BRM/BAF190B and SMARCA4/BRG1/BAF190A. Interacts with
CC       SMARCC1/BAF155. Component of neural progenitors-specific chromatin
CC       remodeling complex (npBAF complex) composed of at least,
CC       ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C,
CC       SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47,
CC       SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, PHF10/BAF45A,
CC       ACTL6A/BAF53A and actin. Component of neuron-specific chromatin
CC       remodeling complex (nBAF complex) composed of at least,
CC       ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C,
CC       SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47,
CC       SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, DPF1/BAF45B,
CC       DPF3/BAF45C, ACTL6B/BAF53B and actin (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       P51531:SMARCA2; NbExp=3; IntAct=EBI-679921, EBI-679562;
CC       P51532:SMARCA4; NbExp=3; IntAct=EBI-679921, EBI-302489;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00355, ECO:0000269|PubMed:11988099}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q8NFD5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NFD5-2; Sequence=VSP_015226;
CC       Name=3;
CC         IsoId=Q8NFD5-3; Sequence=VSP_015227;
CC       Name=4;
CC         IsoId=Q8NFD5-4; Sequence=VSP_040800;
CC   -!- TISSUE SPECIFICITY: Widely expressed with high levels in heart,
CC       skeletal muscle and kidney. {ECO:0000269|PubMed:11988099,
CC       ECO:0000269|PubMed:12200431, ECO:0000269|PubMed:12665591}.
CC   -!- POLYMORPHISM: The poly-Gln region is polymorphic and the number of
CC       Gln varies in the population (from 17 to 23).
CC   -!- DISEASE: Mental retardation, autosomal dominant 12 (MRD12)
CC       [MIM:614562]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with
CC       impairments in adaptive behavior and manifested during the
CC       developmental period. MRD12 patients present with moderate to
CC       severe psychomotor retardation, and most show evidence of muscular
CC       hypotonia. In many patients, expressive speech is more severely
CC       affected than receptive function. Additional common findings
CC       include short stature, abnormal head shape and low-set,
CC       posteriorly rotated, and abnormally shaped ears, downslanting
CC       palpebral fissures, a bulbous nasal tip, a thin upper lip, minor
CC       teeth anomalies, and brachydactyly or single palmar creases.
CC       Autistic features are uncommon. {ECO:0000269|PubMed:22405089,
CC       ECO:0000269|PubMed:22426308, ECO:0000269|PubMed:22426309}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Contains 1 ARID domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00355}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-59 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL76077.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAN70985.1; Type=Frameshift; Positions=857, 863; Evidence={ECO:0000305};
CC       Sequence=CAA69592.1; Type=Frameshift; Positions=132; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF259792; AAG36928.1; -; mRNA.
DR   EMBL; AL355297; CAH71534.1; -; Genomic_DNA.
DR   EMBL; AL049820; CAH71534.1; JOINED; Genomic_DNA.
DR   EMBL; AL162578; CAH71534.1; JOINED; Genomic_DNA.
DR   EMBL; AL591545; CAH71534.1; JOINED; Genomic_DNA.
DR   EMBL; AL049820; CAI42308.1; -; Genomic_DNA.
DR   EMBL; AL162578; CAI42308.1; JOINED; Genomic_DNA.
DR   EMBL; AL355297; CAI42308.1; JOINED; Genomic_DNA.
DR   EMBL; AL591545; CAI42308.1; JOINED; Genomic_DNA.
DR   EMBL; AL162578; CAI40014.1; -; Genomic_DNA.
DR   EMBL; AL049820; CAI40014.1; JOINED; Genomic_DNA.
DR   EMBL; AL355297; CAI40014.1; JOINED; Genomic_DNA.
DR   EMBL; AL591545; CAI40014.1; JOINED; Genomic_DNA.
DR   EMBL; AL591545; CAI40666.1; -; Genomic_DNA.
DR   EMBL; AL049820; CAI40666.1; JOINED; Genomic_DNA.
DR   EMBL; AL162578; CAI40666.1; JOINED; Genomic_DNA.
DR   EMBL; AL355297; CAI40666.1; JOINED; Genomic_DNA.
DR   EMBL; AL049820; CAI42305.1; -; Genomic_DNA.
DR   EMBL; AL591545; CAI42305.1; JOINED; Genomic_DNA.
DR   EMBL; AL591545; CAI40664.1; -; Genomic_DNA.
DR   EMBL; AL049820; CAI40664.1; JOINED; Genomic_DNA.
DR   EMBL; AJ001216; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Y08266; CAA69592.1; ALT_FRAME; mRNA.
DR   EMBL; AF521671; AAN03447.1; -; mRNA.
DR   EMBL; AF253515; AAN70985.1; ALT_SEQ; mRNA.
DR   EMBL; AF468300; AAL76077.1; ALT_INIT; mRNA.
DR   EMBL; AB033061; BAA86549.1; -; mRNA.
DR   CCDS; CCDS5251.2; -. [Q8NFD5-1]
DR   CCDS; CCDS55072.1; -. [Q8NFD5-2]
DR   RefSeq; NP_059989.2; NM_017519.2. [Q8NFD5-1]
DR   RefSeq; NP_065783.3; NM_020732.3. [Q8NFD5-2]
DR   RefSeq; XP_005267126.2; XM_005267069.3. [Q8NFD5-3]
DR   UniGene; Hs.291587; -.
DR   UniGene; Hs.744461; -.
DR   PDB; 2CXY; X-ray; 1.60 A; A=1041-1159.
DR   PDB; 2EH9; X-ray; 2.00 A; A=1041-1159.
DR   PDBsum; 2CXY; -.
DR   PDBsum; 2EH9; -.
DR   ProteinModelPortal; Q8NFD5; -.
DR   SMR; Q8NFD5; 1041-1154.
DR   BioGrid; 121559; 28.
DR   IntAct; Q8NFD5; 10.
DR   MINT; MINT-1153351; -.
DR   STRING; 9606.ENSP00000344546; -.
DR   PhosphoSite; Q8NFD5; -.
DR   BioMuta; ARID1B; -.
DR   DMDM; 73921720; -.
DR   MaxQB; Q8NFD5; -.
DR   PaxDb; Q8NFD5; -.
DR   PRIDE; Q8NFD5; -.
DR   Ensembl; ENST00000346085; ENSP00000344546; ENSG00000049618. [Q8NFD5-2]
DR   Ensembl; ENST00000350026; ENSP00000055163; ENSG00000049618.
DR   GeneID; 57492; -.
DR   KEGG; hsa:57492; -.
DR   UCSC; uc003qqn.3; human. [Q8NFD5-3]
DR   UCSC; uc003qqo.3; human. [Q8NFD5-2]
DR   UCSC; uc003qqp.3; human. [Q8NFD5-1]
DR   CTD; 57492; -.
DR   GeneCards; GC06P157105; -.
DR   GeneReviews; ARID1B; -.
DR   H-InvDB; HIX0006320; -.
DR   H-InvDB; HIX0165033; -.
DR   HGNC; HGNC:18040; ARID1B.
DR   HPA; HPA016511; -.
DR   MIM; 614556; gene.
DR   MIM; 614562; phenotype.
DR   neXtProt; NX_Q8NFD5; -.
DR   Orphanet; 251056; 6q25 microdeletion syndrome.
DR   Orphanet; 1465; Coffin-Siris syndrome.
DR   Orphanet; 3051; intellectual disability - sparse hair - brachydactyly.
DR   PharmGKB; PA134909463; -.
DR   eggNOG; NOG12793; -.
DR   GeneTree; ENSGT00550000074575; -.
DR   HOVERGEN; HBG058196; -.
DR   InParanoid; Q8NFD5; -.
DR   KO; K11653; -.
DR   OMA; AQQRSHP; -.
DR   OrthoDB; EOG7M6D7M; -.
DR   PhylomeDB; Q8NFD5; -.
DR   TreeFam; TF320364; -.
DR   Reactome; REACT_264545; RMTs methylate histone arginines.
DR   ChiTaRS; ARID1B; human.
DR   EvolutionaryTrace; Q8NFD5; -.
DR   GeneWiki; ARID1B; -.
DR   GenomeRNAi; 57492; -.
DR   NextBio; 63782; -.
DR   PRO; PR:Q8NFD5; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; Q8NFD5; -.
DR   CleanEx; HS_ARID1B; -.
DR   ExpressionAtlas; Q8NFD5; baseline and differential.
DR   Genevisible; Q8NFD5; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0071565; C:nBAF complex; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0016514; C:SWI/SNF complex; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:GDB.
DR   GO; GO:0003713; F:transcription coactivator activity; NAS:UniProtKB.
DR   GO; GO:0048096; P:chromatin-mediated maintenance of transcription; NAS:UniProtKB.
DR   GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.150.60; -; 1.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR001606; ARID_dom.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR021906; BAF250/Osa.
DR   Pfam; PF01388; ARID; 1.
DR   Pfam; PF12031; DUF3518; 1.
DR   SMART; SM00501; BRIGHT; 1.
DR   SUPFAM; SSF46774; SSF46774; 1.
DR   PROSITE; PS51011; ARID; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chromatin regulator;
KW   Complete proteome; DNA-binding; Mental retardation; Neurogenesis;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   Transcription; Transcription regulation; Triplet repeat expansion.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:19413330}.
FT   CHAIN         2   2236       AT-rich interactive domain-containing
FT                                protein 1B.
FT                                /FTId=PRO_0000200576.
FT   DOMAIN     1053   1144       ARID. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00355}.
FT   MOTIF       419    423       LXXLL.
FT   MOTIF      2036   2040       LXXLL.
FT   COMPBIAS      2     47       Ala-rich.
FT   COMPBIAS     35     57       Ser-rich.
FT   COMPBIAS     81    104       His-rich.
FT   COMPBIAS    107    131       Gln-rich.
FT   COMPBIAS    114    131       Poly-Gln.
FT   COMPBIAS    141    401       Gly-rich.
FT   COMPBIAS    329    493       Ala-rich.
FT   COMPBIAS    574    633       Gln-rich.
FT   COMPBIAS    684    771       Ser-rich.
FT   COMPBIAS    932    935       Poly-Ala.
FT   COMPBIAS   1034   1037       Poly-Ser.
FT   COMPBIAS   1441   1444       Poly-Ser.
FT   COMPBIAS   1459   1597       Pro-rich.
FT   COMPBIAS   1833   1836       Poly-Pro.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000269|PubMed:19413330}.
FT   MOD_RES     516    516       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648}.
FT   MOD_RES    1555   1555       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:21406692}.
FT   MOD_RES    1559   1559       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES    1715   1715       Phosphoserine.
FT                                {ECO:0000269|PubMed:21406692}.
FT   MOD_RES    1777   1777       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:19608861}.
FT   VAR_SEQ       1    750       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:11734557}.
FT                                /FTId=VSP_040800.
FT   VAR_SEQ     579    579       Q -> QDSGDATWKETFWL (in isoform 2).
FT                                {ECO:0000303|PubMed:11988099}.
FT                                /FTId=VSP_015226.
FT   VAR_SEQ    1032   1032       K -> KDSYSSQGISQPPTPGNLPVPSPMSPSSASISSFHG
FT                                DESDSISSPGWPKTPSSP (in isoform 3).
FT                                {ECO:0000303|PubMed:10574462}.
FT                                /FTId=VSP_015227.
FT   VARIANT      11     11       A -> AA. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067662.
FT   VARIANT      45     47       Missing. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067663.
FT   VARIANT      82     82       Q -> H. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067664.
FT   VARIANT     246    246       G -> S. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067665.
FT   VARIANT     318    319       Missing. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067666.
FT   VARIANT     319    319       Missing. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067667.
FT   VARIANT     327    328       Missing. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067668.
FT   VARIANT     333    337       Missing. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067669.
FT   VARIANT     363    363       A -> V. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067670.
FT   VARIANT     396    396       G -> A. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067671.
FT   VARIANT     429    429       M -> V. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067672.
FT   VARIANT     450    450       P -> PP. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067673.
FT   VARIANT     497    497       S -> N. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067674.
FT   VARIANT     531    531       M -> T. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067675.
FT   VARIANT     814    814       G -> A (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036257.
FT   VARIANT     876    876       Q -> E. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067676.
FT   VARIANT     980    980       Q -> L. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067677.
FT   VARIANT    1092   1092       V -> I. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067678.
FT   VARIANT    1249   1249       Q -> P. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067679.
FT   VARIANT    1271   1271       G -> E. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067680.
FT   VARIANT    1303   1303       G -> R. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067681.
FT   VARIANT    1321   1321       S -> N. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067682.
FT   VARIANT    1411   1411       P -> S. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067683.
FT   VARIANT    1466   1466       Q -> K. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067684.
FT   VARIANT    1506   1506       R -> H. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067685.
FT   VARIANT    1573   1573       T -> M. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067686.
FT   VARIANT    1659   1659       N -> S. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067687.
FT   VARIANT    1733   1733       Missing. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067688.
FT   VARIANT    1773   1773       K -> R. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067689.
FT   VARIANT    1851   1851       D -> N. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067690.
FT   VARIANT    1898   1898       K -> R. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067691.
FT   VARIANT    1954   1954       K -> R. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067692.
FT   VARIANT    2163   2163       Q -> R. {ECO:0000269|PubMed:22405089}.
FT                                /FTId=VAR_067693.
FT   CONFLICT    334    336       AGA -> SRS (in Ref. 5; AAN03447).
FT                                {ECO:0000305}.
FT   CONFLICT    446    446       P -> A (in Ref. 6; AAN70985).
FT                                {ECO:0000305}.
FT   CONFLICT    687    687       V -> A (in Ref. 7; AAL76077).
FT                                {ECO:0000305}.
FT   CONFLICT    904    904       T -> P (in Ref. 7; AAL76077).
FT                                {ECO:0000305}.
FT   CONFLICT   1201   1201       T -> I (in Ref. 1; AAG36928).
FT                                {ECO:0000305}.
FT   CONFLICT   1339   1339       P -> S (in Ref. 6; AAN70985).
FT                                {ECO:0000305}.
FT   CONFLICT   1432   1432       P -> L (in Ref. 8; BAA86549).
FT                                {ECO:0000305}.
FT   CONFLICT   1534   1534       P -> S (in Ref. 6; AAN70985).
FT                                {ECO:0000305}.
FT   CONFLICT   1713   1713       D -> N (in Ref. 7; AAL76077).
FT                                {ECO:0000305}.
FT   CONFLICT   2196   2196       D -> N (in Ref. 1; AAG36928).
FT                                {ECO:0000305}.
FT   HELIX      1046   1049       {ECO:0000244|PDB:2CXY}.
FT   HELIX      1056   1070       {ECO:0000244|PDB:2CXY}.
FT   HELIX      1087   1097       {ECO:0000244|PDB:2CXY}.
FT   HELIX      1100   1106       {ECO:0000244|PDB:2CXY}.
FT   HELIX      1109   1115       {ECO:0000244|PDB:2CXY}.
FT   HELIX      1122   1135       {ECO:0000244|PDB:2CXY}.
FT   HELIX      1137   1145       {ECO:0000244|PDB:2CXY}.
SQ   SEQUENCE   2236 AA;  236123 MW;  4538B4747606C918 CRC64;
     MAHNAGAAAA AGTHSAKSGG SEAALKEGGS AAALSSSSSS SAAAAAASSS SSSGPGSAME
     TGLLPNHKLK TVGEAPAAPP HQQHHHHHHA HHHHHHAHHL HHHHALQQQL NQFQQQQQQQ
     QQQQQQQQQQ QHPISNNNSL GGAGGGAPQP GPDMEQPQHG GAKDSAAGGQ ADPPGPPLLS
     KPGDEDDAPP KMGEPAGGRY EHPGLGALGT QQPPVAVPGG GGGPAAVPEF NNYYGSAAPA
     SGGPGGRAGP CFDQHGGQQS PGMGMMHSAS AAAAGAPGSM DPLQNSHEGY PNSQCNHYPG
     YSRPGAGGGG GGGGGGGGGS GGGGGGGGAG AGGAGAGAVA AAAAAAAAAA GGGGGGGYGG
     SSAGYGVLSS PRQQGGGMMM GPGGGGAASL SKAAAGSAAG GFQRFAGQNQ HPSGATPTLN
     QLLTSPSPMM RSYGGSYPEY SSPSAPPPPP SQPQSQAAAA GAAAGGQQAA AGMGLGKDMG
     AQYAAASPAW AAAQQRSHPA MSPGTPGPTM GRSQGSPMDP MVMKRPQLYG MGSNPHSQPQ
     QSSPYPGGSY GPPGPQRYPI GIQGRTPGAM AGMQYPQQQM PPQYGQQGVS GYCQQGQQPY
     YSQQPQPPHL PPQAQYLPSQ SQQRYQPQQD MSQEGYGTRS QPPLAPGKPN HEDLNLIQQE
     RPSSLPDLSG SIDDLPTGTE ATLSSAVSAS GSTSSQGDQS NPAQSPFSPH ASPHLSSIPG
     GPSPSPVGSP VGSNQSRSGP ISPASIPGSQ MPPQPPGSQS ESSSHPALSQ SPMPQERGFM
     AGTQRNPQMA QYGPQQTGPS MSPHPSPGGQ MHAGISSFQQ SNSSGTYGPQ MSQYGPQGNY
     SRPPAYSGVP SASYSGPGPG MGISANNQMH GQGPSQPCGA VPLGRMPSAG MQNRPFPGNM
     SSMTPSSPGM SQQGGPGMGP PMPTVNRKAQ EAAAAVMQAA ANSAQSRQGS FPGMNQSGLM
     ASSSPYSQPM NNSSSLMNTQ APPYSMAPAM VNSSAASVGL ADMMSPGESK LPLPLKADGK
     EEGTPQPESK SKKSSSSTTT GEKITKVYEL GNEPERKLWV DRYLTFMEER GSPVSSLPAV
     GKKPLDLFRL YVCVKEIGGL AQVNKNKKWR ELATNLNVGT SSSAASSLKK QYIQYLFAFE
     CKIERGEEPP PEVFSTGDTK KQPKLQPPSP ANSGSLQGPQ TPQSTGSNSM AEVPGDLKPP
     TPASTPHGQM TPMQGGRSST ISVHDPFSDV SDSSFPKRNS MTPNAPYQQG MSMPDVMGRM
     PYEPNKDPFG GMRKVPGSSE PFMTQGQMPN SSMQDMYNQS PSGAMSNLGM GQRQQFPYGA
     SYDRRHEPYG QQYPGQGPPS GQPPYGGHQP GLYPQQPNYK RHMDGMYGPP AKRHEGDMYN
     MQYSSQQQEM YNQYGGSYSG PDRRPIQGQY PYPYSRERMQ GPGQIQTHGI PPQMMGGPLQ
     SSSSEGPQQN MWAARNDMPY PYQNRQGPGG PTQAPPYPGM NRTDDMMVPD QRINHESQWP
     SHVSQRQPYM SSSASMQPIT RPPQPSYQTP PSLPNHISRA PSPASFQRSL ENRMSPSKSP
     FLPSMKMQKV MPTVPTSQVT GPPPQPPPIR REITFPPGSV EASQPVLKQR RKITSKDIVT
     PEAWRVMMSL KSGLLAESTW ALDTINILLY DDSTVATFNL SQLSGFLELL VEYFRKCLID
     IFGILMEYEV GDPSQKALDH NAARKDDSQS LADDSGKEEE DAECIDDDEE DEEDEEEDSE
     KTESDEKSSI ALTAPDAAAD PKEKPKQASK FDKLPIKIVK KNNLFVVDRS DKLGRVQEFN
     SGLLHWQLGG GDTTEHIQTH FESKMEIPPR RRPPPPLSSA GRKKEQEGKG DSEEQQEKSI
     IATIDDVLSA RPGALPEDAN PGPQTESSKF PFGIQQAKSH RNIKLLEDEP RSRDETPLCT
     IAHWQDSLAK RCICVSNIVR SLSFVPGNDA EMSKHPGLVL ILGKLILLHH EHPERKRAPQ
     TYEKEEDEDK GVACSKDEWW WDCLEVLRDN TLVTLANISG QLDLSAYTES ICLPILDGLL
     HWMVCPSAEA QDPFPTVGPN SVLSPQRLVL ETLCKLSIQD NNVDLILATP PFSRQEKFYA
     TLVRYVGDRK NPVCREMSMA LLSNLAQGDA LAARAIAVQK GSIGNLISFL EDGVTMAQYQ
     QSQHNLMHMQ PPPLEPPSVD MMCRAAKALL AMARVDENRS EFLLHEGRLL DISISAVLNS
     LVASVICDVL FQIGQL
//
